X0508 4 2024-02-27 false 0001645113 NovoCure Ltd NVCR 0001264783 GROENHUYSEN WILHELMUS CM C/O NOVOCURE INC. 1550 LIBERTY RIDGE DRIVE, SUITE 115 WAYNE PA 19087 false true false false Chief Operating Officer false Ordinary Shares 2023-12-31 5 A false E 3.00 12.69 A 209828.00 D Ordinary Shares 2024-02-27 4 A false 47034.00 16.30 A 256862.00 D Ordinary Shares 2024-02-28 4 S false 2303.00 16.1428 D 254559.00 D Stock Options (Right to buy) 16.30 2024-02-27 4 A false 71920.00 16.30 A 2025-02-27 2034-02-26 Ordinary Shares 71920.00 71920.00 D The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2023 through December 31, 2023. This transaction is also exempt under Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2023. Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Options to buy 71,920 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates. Steven Robbins, as attorney in fact for Groenhuysen, Wilhelmus CM 2024-02-29